Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Conclusions: Single-agent therapy with gilteritinib induced deep molecular responses, including MRD negativity, in heavily pretreatedpatients with FLT3-ITDmut+ R/R AML. Our results suggest a potential association between MRD-negative status and longer survival in patients withFLT3-ITDmut+ R/R AML. Additionally, patients who achieved CR/CRh appear to have both a higher rate of MRD negativity and longer OS than patients who did not achieve CR/CRh.DisclosuresPerl: Daiichi Sankyo: Consultancy; Astellas: Consultancy; NewLink Genetics: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Actinium Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Arog: Consultancy; AbbVie: Membership on an entity's Board of Directors or advisory committees. Altman: Syros: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; GSK: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Pfizer: Other: payment to the institution to conduct clinical trial work; Cycla...
Source: Blood - Category: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Source Type: research